The global single-use bioreactors market was valued at USD 4.42 billion in 2024 and is projected to grow from USD 4.81 billion in 2025 to USD 10.42 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 9.0% during the forecast period from 2025 to 2034. This growth is primarily driven by the increasing demand for biopharmaceuticals, the adoption of single-use technology in bioprocessing, and advancements in cell culture techniques for the production of biologics and vaccines.
Single-use bioreactors, also known as disposable bioreactors, are systems that allow for the cultivation of cells in controlled environments for various applications in the biotechnology and pharmaceutical industries. The market for these bioreactors is expanding rapidly as companies shift towards more cost-effective, flexible, and efficient production processes. The trend of adopting single-use systems has become particularly prominent due to their ability to streamline production processes, reduce contamination risks, and eliminate the need for costly cleaning and sterilization procedures associated with traditional bioreactor systems.
Market Overview
A bioreactor system is a vessel used to provide a controlled environment for growing cells and microorganisms. These systems are integral to biopharmaceutical production, particularly for the manufacture of vaccines, monoclonal antibodies, and other biologic therapies. Traditionally, bioreactors were reusable, requiring extensive cleaning, sterilization, and validation between batches. However, advancements in single-use technology have led to the widespread adoption of disposable bioreactors, which significantly reduce operational complexities and increase production flexibility.
Single-use bioreactors are designed to be used for one production cycle only, and then discarded. These systems offer several advantages over traditional stainless-steel bioreactors, such as reduced cross-contamination risks, increased scalability, and faster turnaround times. They are commonly used in cell culture applications, including upstream processing in biopharmaceutical manufacturing. These advantages are driving a substantial shift in the market, as companies seek more efficient and cost-effective solutions in biologics production.
The biopharmaceuticals industry, in particular, is a key driver of growth in the single-use bioreactor market. As the global demand for biologic therapies continues to increase, biopharmaceutical companies are turning to bioreactor systems to scale up their production processes and meet the needs of the market. Additionally, the increasing use of cell culture for the production of vaccines, gene therapies, and cell-based therapeutics is further propelling the demand for single-use bioreactors.
ππ±π©π₯π¨π«π ππ‘π ππ¨π¦π©π₯πππ ππ¨π¦π©π«ππ‘ππ§π¬π’π―π πππ©π¨π«π πππ«π:
https://www.polarismarketresearch.com/industry-analysis/single-use-bioreactors-market
Market Segmentation
The single-use bioreactors market is segmented based on type, application, end-user, and region.
1. By Type:
Stirred-Tank Bioreactors
Wave-Induced Motion Bioreactors
Axial-Flow Bioreactors
Others
Stirred-tank bioreactors are the most widely used in both traditional and single-use formats. These bioreactors offer excellent mixing capabilities, which is essential for growing cells in suspension cultures. The growing demand for monoclonal antibodies and protein therapeutics is expected to maintain the strong demand for stirred-tank systems.
Wave-induced motion bioreactors are gaining popularity, especially in research and development settings. These bioreactors are known for their ability to reduce shear stress, making them ideal for culturing sensitive cells like stem cells. As cell culture techniques advance, the adoption of wave-induced motion systems is expected to increase.
Axial-flow bioreactors, while a newer type of single-use system, offer a promising solution for large-scale applications. These bioreactors are known for their efficient mixing and aeration, which can improve yields in larger cultures. Their adoption is expected to rise as biopharmaceuticals shift toward larger-scale, more efficient production systems.
2. By Application:
Monoclonal Antibody Production
Vaccine Production
Cell and Gene Therapy
Recombinant Protein Production
Others
Monoclonal antibody production is one of the largest applications for single-use bioreactors. The demand for monoclonal antibodies has increased significantly in recent years, as these therapeutics are used for treating a variety of conditions, including cancer, autoimmune diseases, and infectious diseases. Single-use bioreactors are well-suited for the production of monoclonal antibodies due to their ability to scale up quickly and provide a controlled environment for cell cultures.
Vaccine production is another key application driving the adoption of single-use bioreactors. The COVID-19 pandemic underscored the need for efficient and scalable vaccine production, prompting greater use of single-use bioreactors in vaccine development and manufacturing.
The rise of cell and gene therapies is also boosting the demand for single-use systems. These therapies often involve the manipulation of patient cells, which requires precise control over the culture environment. Single-use bioreactors are increasingly used to facilitate the production of these advanced therapies.
Recombinant protein production, which is used to create therapeutic proteins, enzymes, and hormones, is another major application area for single-use bioreactors. As the demand for biologics continues to rise, these bioreactors play a crucial role in the production process.
3. By End-User:
Biopharmaceutical Companies
Contract Development and Manufacturing Organizations (CDMOs)
Research and Academic Institutions
Others
Biopharmaceutical companies are the largest end-users of single-use bioreactors. These companies are focused on developing and manufacturing biologic drugs, including monoclonal antibodies, vaccines, and recombinant proteins. As demand for these biologics increases, so too does the need for flexible and efficient production technologies like single-use bioreactors.
Contract development and manufacturing organizations (CDMOs) play a key role in the biopharmaceutical supply chain by providing outsourced manufacturing services for drug development and production. CDMOs are increasingly adopting single-use bioreactors as they offer a cost-effective and scalable solution for their clients in the biopharmaceutical industry.
Research and academic institutions also use single-use bioreactors for research and development purposes, particularly in cell culture studies, protein production, and vaccine development.
Regional Analysis
1. North America:
North America is expected to hold the largest share of the global single-use bioreactor market. The United States, in particular, is a major consumer of single-use bioreactors, driven by its advanced biopharmaceutical industry and the presence of leading biomanufacturing companies. The increasing adoption of bioprocessing technologies and the growing demand for biologics are contributing to the expansion of the market in this region.
Canada is also experiencing growth in the single-use bioreactor market, with a strong focus on the development of biologics and vaccines, particularly in research and development settings.
2. Europe:
Europe is another key market for single-use bioreactors, with significant growth driven by countries such as Germany, the UK, and Switzerland. The European market is fueled by a rising demand for biopharmaceuticals, especially monoclonal antibodies, and the increasing shift towards disposable bioprocessing technologies in pharmaceutical manufacturing.
3. Asia-Pacific (APAC):
The Asia-Pacific (APAC) region is expected to grow at the highest rate during the forecast period. Key markets like China, Japan, and India are experiencing rapid advancements in their biopharmaceutical and biotechnology industries. As demand for biologics and vaccines continues to rise in APAC, the adoption of single-use technology in bioreactor systems is accelerating.
4. Latin America & Middle East & Africa (LAMEA):
The Latin America and Middle East & Africa (LAMEA) region is experiencing steady growth, primarily driven by increasing healthcare investments and the expansion of the biopharmaceutical industry. The adoption of single-use bioreactors is gaining momentum in emerging markets, where there is a growing focus on improving healthcare infrastructure.
Key Companies and Competitive Landscape
The single-use bioreactor market is highly competitive, with several large and medium-sized players leading the market. Some of the key companies include:
1. Sartorius AG
Sartorius is one of the leaders in the single-use bioreactor market, offering a wide range of bioreactor systems for cell culture and biopharmaceutical production. The company is known for its innovative solutions and focus on improving bioprocessing efficiency.
2. Thermo Fisher Scientific
Thermo Fisher is another major player in the market, providing a comprehensive range of single-use bioreactors and bioprocessing technologies. The company is committed to advancing biopharmaceutical manufacturing processes and offering scalable solutions.
3. GE Healthcare
GE Healthcare provides single-use bioreactors through its HyClone product line. The company is recognized for its high-quality solutions designed to support cell culture, protein production, and vaccine manufacturing.
4. Eppendorf AG
Eppendorf is a prominent player in the bioreactor market, offering a variety of single-use and reusable bioreactor systems for research and commercial production.
Other key players include Merck KGaA, Danaher Corporation, and Pall Corporation.
Market Trends and Future Outlook
Adoption of Biopharmaceuticals: The increasing production of biologic therapies, such as monoclonal antibodies and vaccines, is driving the demand for single-use bioreactors.
Technological Advancements: Ongoing advancements in bioprocessing technology, including automation and integration with other systems, will further enhance the capabilities and adoption of single-use bioreactors.
Cost-Efficiency: The continued focus on reducing production costs and improving operational efficiency will boost the demand for single-use technology in bioreactor systems.
Conclusion
The global single-use bioreactor market is poised for strong growth, projected to reach USD 10.42 billion by 2034. As demand for biopharmaceuticals, vaccines, and cell culture applications continues to rise, single-use bioreactors will play an increasingly vital role in enhancing bioprocessing efficiency and flexibility. With continued technological innovations and greater adoption across regions, the market for single-use bioreactors is set to experience significant expansion in the coming years.
More Trending Latest Reports By Polaris Market Research:
Patient Handling Equipment Market
Compressed Air Filter & Dryer Market
Open Radio Access Network (Open RAN) Market
Alternative Coffee-Based Products Market